Quantitative and Translational Medicine Laboratory
The Quantitative and Translational Medicine Laboratory focuses on the application and implementation of quantitative approaches, particularly computational biology, to study biologically-relevant questions of large medical importance, with a particular emphasis on the optimization of treatment strategies for a variety of diseases. Dr Craig’s current projects include understanding pre-leukemic hematopoietic stem cell dynamics, PBPK/PD models of antiretroviral drugs to support the design of a novel sustained-release delivery device for improved HIV treatment design and HIV cure strategies, unravelling immunological networks during rare diseases, and quantifying the impact of heterogeneity in glioblastoma, melanoma, and non-small cell lung cancer tumours on resistance pathways and ultimate therapy success. Dr. Craig’s research is highly multidisciplinary and is conducted in close collaboration with experimentalists and clinicians.
Dr. Craig received her PhD in Pharmaceutical Sciences from the University of Montreal in 2016, during which she studied the optimization of prophylactic G-CSF support to mitigate neutropenia during periodic chemotherapy. During her postdoctoral fellowship at the Program for Evolutionary Dynamics at Harvard University, she worked to develop an integrated in silico platform to predict virologic outcomes of conventional and proposed highly-active antiretrovial therapy (HAART) for pre-exposure prophylaxis and anti-HIV treatment. She joined the Department of Mathematics and Statistics at the University of Montreal in 2018. Her work focuses on understanding pathophysiological mechanisms and treatment optimization in a variety of cancers and hemato-immune diseases. She joined the CHU Sainte-Justine Research Centre in 2020.
PubMed
The CHU Sainte-Justine collaborates in a study funded by the National Institute of Allergy and Infectious Diseases (NIAID)